↓ Skip to main content

Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease

Overview of attention for article published in Stem Cell Research & Therapy, August 2018
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
2 tweeters

Readers on

mendeley
35 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease
Published in
Stem Cell Research & Therapy, August 2018
DOI 10.1186/s13287-018-0960-8
Pubmed ID
Authors

Cinzia Rota, Marina Morigi, Domenico Cerullo, Martino Introna, Ornella Colpani, Daniela Corna, Chiara Capelli, Ton J. Rabelink, Danielle G. Leuning, Daniela Rottoli, Ariela Benigni, Carlamaria Zoja, Giuseppe Remuzzi

Abstract

Mesenchymal stromal cell (MSC)-based therapy is a promising strategy for preventing the progression of chronic kidney disease (CKD), with the potential to induce tissue regeneration. In search of the best cellular source we compared, in the rat model of adriamycin (ADR) nephropathy, the regenerative potential of human stromal cells of non-renal origin, such as bone marrow (bm) MSCs and umbilical cord (uc) MSCs, with that of newly discovered stromal cells of renal origin, the kidney perivascular cells (kPSCs) known to exhibit tissue-specific properties. The therapeutic effect of repeated infusions of human bmMSCs, ucMSCs, kPSCs (1.5 × 106 cells/rats) or conditioned medium from ucMSCs was studied in athymic rats with ADR-induced nephropathy (7.9 mg/kg). The ability of the three stromal cell populations to engraft the damaged kidney was evaluated by detecting the presence of human nuclear antigenpos cells. Glomerular podocyte loss and endothelial damage, sclerotic lesions and inflammation were assessed at 14 and 28 days. In-vitro experiments with a transwell system were performed to investigate the effects of different stromal cell populations on parietal epithelial cells (PECs) activated or not with albumin or angiotensin II for 24 h. Infusions of non-renal and renal stromal cells resulted in a comparable engraftment into the kidney, in the peritubular areas and around the glomerular structures. All three cell populations limited podocyte loss and glomerular endothelial cell injury, and attenuated the formation of podocyte and PEC bridges. This translated into a reduction of glomerulosclerosis and fibrosis. Human ucMSCs had an anti-inflammatory effect superior to that of the other stromal cells, reducing macrophage infiltration and inducing polarisation towards the M2 macrophage phenotype. Conditioned medium from ucMSCs shared the same renoprotective effects of the cells. Consistent with in-vivo data, bmMSCs and kPSCs, but even more so ucMSCs, limited proliferation, migratory potential and extracellular matrix production of activated PECs, when cultured in a transwell system. Our data indicate that either non-renal or renal stromal cells induce renal tissue repair, highlighting ucMSCs and their conditioned medium as the most reliable clinical therapeutic tool for CKD patients.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 35 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 8 23%
Student > Ph. D. Student 6 17%
Other 4 11%
Student > Master 4 11%
Student > Doctoral Student 1 3%
Other 5 14%
Unknown 7 20%
Readers by discipline Count As %
Medicine and Dentistry 7 20%
Biochemistry, Genetics and Molecular Biology 7 20%
Pharmacology, Toxicology and Pharmaceutical Science 4 11%
Nursing and Health Professions 2 6%
Unspecified 1 3%
Other 4 11%
Unknown 10 29%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 August 2018.
All research outputs
#8,421,820
of 13,441,462 outputs
Outputs from Stem Cell Research & Therapy
#686
of 1,181 outputs
Outputs of similar age
#160,537
of 268,619 outputs
Outputs of similar age from Stem Cell Research & Therapy
#2
of 2 outputs
Altmetric has tracked 13,441,462 research outputs across all sources so far. This one is in the 23rd percentile – i.e., 23% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,181 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 268,619 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one.